$1.17
0.010.86%
At Close: -
$1.16
-0.01-0.85%
After Hours: Jul 3, 4:39 PM EDT
15 minutes delayed
Atossa Therapeutics
ATOSNASDAQ
Atossa Therapeutics (NASDAQ:ATOS) Stock, Analyst Ratings, Price Targets, Predictions
Atossa Therapeutics Inc has a consensus price target of $4.08, established from looking at the 9 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Ascendiant Capital, and HC Wainwright & Co. on June 28, 2024, June 6, 2024, and May 13, 2024. With an average price target of $6.08 between HC Wainwright & Co., Ascendiant Capital, and HC Wainwright & Co., there's an implied 424.43% upside for Atossa Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
Ascendiant Capital
1calculated from analyst ratings
Analyst Ratings for Atossa Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/28/2024 | Buy Now | 417.24% | HC Wainwright & Co. | Emily Bodnar | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 06/06/2024 | Buy Now | 438.79% | Ascendiant Capital | Edward Woo | $6 → $6.25 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 05/13/2024 | Buy Now | 417.24% | HC Wainwright & Co. | Emily Bodnar | $4 → $6 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 244.83% | HC Wainwright & Co. | Emily Bodnar | → $4 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | Buy Now | 244.83% | HC Wainwright & Co. | Emily Bodnar | $4 → $4 | Maintains | Buy | Get Alert |
| 02/12/2024 | Buy Now | 244.83% | HC Wainwright & Co. | Emily Bodnar | → $4 | Initiates | → Buy | Get Alert |
| 09/08/2023 | Buy Now | 331.03% | Cantor Fitzgerald | Louise Chen | → $5 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Atossa Therapeutics (ATOS) stock?
The latest price target for Atossa Therapeutics (NASDAQ:ATOS) was reported by HC Wainwright & Co. on June 28, 2024. The analyst firm set a price target for $6.00 expecting ATOS to rise to within 12 months (a possible 417.24% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atossa Therapeutics (ATOS)?
The latest analyst rating for Atossa Therapeutics (NASDAQ:ATOS) was provided by HC Wainwright & Co., and Atossa Therapeutics reiterated their buy rating.
When was the last upgrade for Atossa Therapeutics (ATOS)?
There is no last upgrade for Atossa Therapeutics
When was the last downgrade for Atossa Therapeutics (ATOS)?
There is no last downgrade for Atossa Therapeutics.
When is the next analyst rating going to be posted or updated for Atossa Therapeutics (ATOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atossa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atossa Therapeutics was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
Is the Analyst Rating Atossa Therapeutics (ATOS) correct?
While ratings are subjective and will change, the latest Atossa Therapeutics (ATOS) rating was a reiterated with a price target of $6.00 to $6.00. The current price Atossa Therapeutics (ATOS) is trading at is $1.16, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.